SuperworthCamp4 Therapeutics CAMP
- Market cap
- $207.1M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 49.1×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $4.2M
- +40% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −13.9%
Camp4 Therapeutics trades at 49.1× sales. Its trailing earnings are negative, so it has no PE. Revenue was $4.2M over the last twelve months, up 40% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $350K | $0 | $0 | $0 | $0 | $652K | $858K | $1.5M | $795K | $348K−47% | $1.3M+51% | $1.8M+19% | |
| R&D | $9.8M | $10.7M | $9.7M | $9.4M | $9.7M−1% | $10M−6% | $10.1M+4% | $10.3M+10% | $9.4M−4% | $8.4M−16% | $10.2M+0% | $10.8M+5% |
| SG&A | $2.9M | $2.8M | $3.1M | $3.3M | $3.8M+33% | $4.7M+67% | $3.8M+22% | $4.2M+28% | $4.6M+21% | $4.8M+2% | $4.2M+10% | $4.3M+4% |
| −$12.3M | −$13.5M | −$12.9M | −$12.7M | −$13.5M+10% | −$14M+4% | −$13.1M+2% | −$13M+3% | −$13.7M+1% | −$12.8M−9% | −$13.1M−0% | −$13.4M+3% | |
| Net income | −$11.7M | −$13M | −$12.5M | −$12.6M | −$13.5M+15% | −$13.3M+2% | −$12.4M−0% | −$12.6M+0% | −$15.1M+12% | −$40.3M+203% | −$18.3M+47% | −$33.5M+166% |
| −$29.21 | −$30.31 | −$26.57 | −$26.00 | −$24.19−17% | n/a | −$0.62−98% | −$0.62−98% | −$0.55−98% | −$0.75 | −$0.32−48% | −$0.58−7% | |
| 400.4K | 428.6K | 468.7K | 483.6K | 557.4K+39% | n/a | 20.2M+4200% | 20.2M+4068% | 27.3M+4793% | 53.6M | 57.9M+187% | 57.9M+187% |
EPS, diluted: Q4 FY23 and Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY23 and Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Camp4 Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CAMPCamp4 Therapeutics | $207.1M | n/m | n/a | 49.1× | +40% | n/m | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| ABUSArbutus Biopharma | $831M | 5.4× | 5.6× | 4.6× | n/m | 84.2% | |
| Peer median | $570.3M | 11.3× | 13.6× | 1.4× | +7% | 13.6% |
More on Camp4 Therapeutics
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .